Pomerantz Law Firm Explores Claims for Soleno Investors
Pomerantz LLP, a well-respected law firm, is actively investigating claims on behalf of investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO). This action is being taken to determine if Soleno and some of its officials may have engaged in securities fraud or unlawful business practices that could have affected investors adversely.
Concerns Over Vykat XR
One of the significant issues that have surfaced during this investigation pertains to Soleno's primary product, Vykat XR. A critical report released recently raised several alarms regarding the pricing of Vykat XR, suggesting it may be excessively priced and potentially unsafe for children. Such claims are concerning, especially given the sensitive nature of products targeted towards young audiences.
The Impact on Stock Price
The release of the report by Scorpion Capital on August 15, 2025, had a direct impact on Soleno's stock value. The stock price saw a significant drop of $5.73 per share, translating to a decline of 7.41%, closing at $71.63 per share on that same day. This kind of fluctuation raises serious concerns and highlights the potential risks faced by current and prospective investors.
Why Investors Should Stay Informed
It is crucial for investors to remain informed as the investigation unfolds. Pomerantz LLP, known for its extensive experience and success in corporate litigation, will be providing guidance and support to investors who might have been affected. Individuals with concerns are encouraged to get in touch with the firm for further assistance.
Beginnings of Pomerantz LLP
Pomerantz LLP has built a formidable reputation over its 85-plus years of operation. Founded by Abraham L. Pomerantz, a pioneer in securities class actions, the firm has worked tirelessly to champion the rights of individuals who fall victim to securities fraud and corporate misconduct. The firm’s notable achievements include recovering substantial damages for class members in various high-profile cases.
How to Reach Pomerantz LLP
For investors seeking further information or looking to discuss their situation regarding Soleno Therapeutics, they can connect with Danielle Peyton at Pomerantz LLP by calling 646-581-9980, ext. 7980. Additionally, inquiries can be directed via email.
Frequently Asked Questions
What is the reason Pomerantz is investigating Soleno Therapeutics?
The firm is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics and its officers.
How can investors contact Pomerantz LLP?
Investors can contact Danielle Peyton at 646-581-9980, ext. 7980 or via email for inquiries related to the investigation.
What was the impact on Soleno's stock price after the report?
Following the report, Soleno's stock price dropped by $5.73 per share, approximately 7.41% on that day.
What are the main concerns regarding Soleno's product, Vykat XR?
Concerns include the product being overpriced and potentially unsafe for children, which raises a red flag for many stakeholders.
What has been Pomerantz's history in securities litigation?
Pomerantz has over 85 years of experience in securities class actions and has recovered significant damages for clients over the years.
